PATH as a volatile AI biotech-like chart
The bull case presented for UiPath was that its high volatility and recent Citi upgrade, following a significant post-earnings drop, presented a potential entry point.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.